Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

104.08 -1.88 (-1.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
54 55 Next >
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
From Gilead Sciences, Inc.
Via Business Wire
Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer
Gilead Sciences Inc (NASDAQ: GILD) decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility  
Via Benzinga
Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Expert Ratings for Gilead Sciences
Via Benzinga
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
From Gilead Sciences, Inc.
Via Business Wire
Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives
DeSantis made it clear that he thinks companies should only maximize profit and be subject to shareholder lawsuits if they do anything other than maximizing profits. So how does this get us to suing... 
Via Talk Markets
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
From Gilead Sciences, Inc.
Via Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
From The Center for Disease Analysis Foundation
Via Business Wire
Price Over Earnings Overview: Gilead Sciences
Via Benzinga
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
From Gilead Sciences, Inc.
Via Business Wire
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
From CDA Foundation
Via GlobeNewswire
2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street
The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future. 
Via The Motley Fool
The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023
The market is soaring, but there is still time to buy these seven undervalued Nasdaq stocks before they head higher. 
Via InvestorPlace
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
From Gilead Sciences, Inc.
Via Business Wire
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
It helps to offer products everyone needs. 
Via The Motley Fool
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
Read the latest report on NanoViricides here. 
Via Benzinga
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
These stocks are built to withstand a bear market. 
Via The Motley Fool
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
From Gilead Sciences, Inc.
Via Business Wire
FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment
The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment,  
Via Benzinga
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
From Gilead Sciences, Inc.
Via Business Wire
7 Tech Stocks to Watch on July 14
Tech stocks are on the rise today ahead of the upcoming Nasdaq 100 rebalancing, the changes for which will be announced this Friday, July 14. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.